VTE-BLEED评分在静脉血栓栓塞症患者长期大出血风险中的验证:来自COMMAND VTE注册研究
COMMAND VTE注册研究纳入2124例延长抗凝超过30天的急性症状性VTE患者,按VTE-BLEED评分分为高风险组(≥2分,1445例)和低风险组(<2分,679例)。
要点
- VTE-BLEED评分≥2分的高风险组5年大出血发生率13.2%,显著高于低风险组的5.4%。
- 风险函数曲线显示高风险组大出血风险随时间持续高于低风险组。
- 该评分可用于非选择性VTE人群延长抗凝治疗时的大出血风险分层。
核心结论
- 在真实世界非选择性VTE注册研究中,VTE-BLEED评分对延长抗凝治疗期间的大出血具有长期预测能力,有助于个体化确定抗凝疗程。
研究设计与样本
- COMMAND VTE注册研究为日本29个中心的多中心回顾性注册研究,纳入连续急性症状性VTE患者。
- 本研究人群为2124例延长抗凝治疗超过30天的患者,其中2008例(95%)为首发VTE,1075例(51%)为无诱因VTE。
- 患者分为VTE-BLEED评分≥2分的高风险组1445例(68%)和<2分的低风险组679例(32%)。
主要发现
- 中位随访672天期间,共121例患者发生大出血事件。
- 风险函数曲线显示高风险组的大出血风险随时间持续高于低风险组,提示评分的长期预测能力。
关键数值与推荐
- VTE-BLEED评分≥2分定义为高风险组,<2分为低风险组。
- 延长抗凝治疗定义为超过30天。
临床怎么用
- 对于延长抗凝治疗的VTE患者,可采用VTE-BLEED评分识别大出血高风险患者(评分≥2分)。
- 高风险患者应加强出血监测,并个体化评估抗凝疗程的获益与风险。
局限性
- 本研究为回顾性注册研究,可能存在未测量混杂因素。
- 研究人群为日本患者,结果外推至其他种族人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recently proposed VTE-BLEED score to predict the risk of major bleeding in patients with venous thromboembolisms (VTEs) on prolonged anticoagulation therapy was validated externally in randomized controlled trials and in a selected cohort, but not applied in non-selective cohorts. OBJECTIVES: The present study aimed to evaluate the generalizability of the VTE-BLEED score in a non-selective cohort. PATIENTS/METHODS: The COMMAND VTE Registry is a multicenter retrospective registry enrolling consecutive patients with acute symptomatic VTEs among 29 centers in Japan. The present study population consisted of 2124 patients with prolonged anticoagulation therapy beyond 30 days, including 2008 (95%) patients with a first VTE episode and 1075 (51%) with unprovoked VTEs, who were divided into 1445 patients (68%) with a VTE-BLEED score of ≥2 (high-risk group) and 679 (32%) with a VTE-BLEED score of <2 (low-risk group). RESULTS: During a median follow-up period of 672 days, major bleeding events occurred in 121 patients. The cumulative 5-year incidence of major bleeding beyond 30 days was significantly higher in the high-risk group than low-risk group (13.2% versus 5.4%, P < .001). The hazard function curves demonstrated that the hazards of the high-risk group were consistently higher over time compared with the low-risk group, which suggested the long-term predictive ability of the score. CONCLUSIONS: In the present real-world VTE registry, the VTE-BLEED score had a long-term predictive ability for high-risk patients with major bleeding during prolonged anticoagulation therapy, which could be useful in determining the optimal duration of anticoagulation therapy in individual patients.
引用
- Nishimoto Y, Yamashita Y, Morimoto T, et al. Validation of the VTE-BLEED score's long-term performance for major bleeding in patients with venous thromboembolisms: From the COMMAND VTE registry. J Thromb Haemost. 2019. PMID: 31785073. doi:10.1111/jth.14691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。